Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon‐based anti‐viral therapy

The purpose of this study was to evaluate the usefulness of liver stiffness measurement (LSM) for assessing the risk of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients receiving interferon (IFN) therapy.

[1]  A. Pollett,et al.  Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients , 2012, Hepatology.

[2]  N. Sugiura,et al.  Occurrence of Hepatocellular Carcinoma Was Not a Rare Event during and Immediately after Antiviral Treatment in Japanese HCV-Positive Patients , 2011, Oncology.

[3]  William M. Lee,et al.  Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. , 2011, Gastroenterology.

[4]  William M. Lee,et al.  Outcome of sustained virological responders with histologically advanced chronic hepatitis C , 2010, Hepatology.

[5]  V. de Lédinghen,et al.  Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.

[6]  N. Kato,et al.  Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography , 2009, Hepatology.

[7]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[8]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[9]  Paul Calès,et al.  Sources of variability in histological scoring of chronic viral hepatitis , 2005, Hepatology.

[10]  T. Ide,et al.  Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon , 2005, Journal of Gastroenterology.

[11]  Y. Ohashi,et al.  Antiviral Therapy for Cirrhotic Hepatitis C: Association with Reduced Hepatocellular Carcinoma Development and Improved Survival , 2005, Annals of Internal Medicine.

[12]  Christos Christidis,et al.  Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C , 2005, Hepatology.

[13]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[14]  Akihiro Matsumoto,et al.  Hepatocellular carcinoma: recent trends in Japan. , 2004, Gastroenterology.

[15]  Y. Imai,et al.  Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy , 2004, Cancer.

[16]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[17]  Chien-Jen Chen,et al.  Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. , 2003, American journal of epidemiology.

[18]  T. Hassanein,et al.  Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection , 2001, American Journal of Gastroenterology.

[19]  S. Hadziyannis,et al.  Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a meta‐analysis , 2001, Alimentary pharmacology & therapeutics.

[20]  P. Andreone,et al.  Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. , 2001, Journal of hepatology.

[21]  J. Brown.  Interferon therapy reduces the risk for hepatocellular carcinoma , 2000, Gut.

[22]  Arakawa,et al.  Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C – a study of 527 patients at one establishment , 2000, Journal of viral hepatitis.

[23]  S Chevret,et al.  Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death , 2000, Gut.

[24]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[25]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[26]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[27]  B. Maharaj,et al.  SAMPLING VARIABILITY AND ITS INFLUENCE ON THE DIAGNOSTIC YIELD OF PERCUTANEOUS NEEDLE BIOPSY OF THE LIVER , 1986, The Lancet.

[28]  E. Mezey,et al.  Sampling variability on percutaneous liver biopsy. , 1979, Archives of internal medicine.

[29]  Plumley Pf.  Letter: the consultants' contract. , 1975, Lancet.

[30]  C. la Vecchia,et al.  The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Bruzzi,et al.  Liver biopsy. , 2001, The New England journal of medicine.